Fig. 7. Reducing bassoon levels improves behavioral deficit and diminishes pathological tau species in a late stage of pathology.
a–d, Two-paw test (a), four-paw test (b), body temperature (c) and frailty test (d) in 9-month-old WT and PS19 mice injected with shBSN or scramble shRNA. e, Hippocampal MC1 immunostaining in 9-month-old PS19 mice injected with shBSN and scramble shRNA. Scale bars, 200 µm and 50 µm for CA1 and CA3 insets, respectively. f, Quantification of MC1 immunostaining in shBSN and scramble PS19 mice as a percentage of area. g–i, Western blot (g), and quantification of specific antibodies against pTau-Ser396/Ser404 (PHF1; h), and pTau-Thr231 (i), in shBSN and scramble PS19 mouse brain lysates. j, Total human tau levels by ELISA in shBSN and scrambled PS19 mouse brain lysates. Experiments were performed with n = 20 for WTscramble, n = 21 for PS19scramble, n = 22 for WTshBSN and n = 16 for PS19shBSN mice (a–d), and n = 8 (e–j). Significance was determined by one-way ANOVA (a–d) and unpaired two-tailed Student’s t-test (f and h–j). Bar graphs with error bars indicate the mean ± s.e.m.